Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis
- 29 March 2010
- journal article
- other
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 16 (6) , 660-669
Abstract
Magnetization transfer ratio (MTR) is a sensitive parameter to quantify the integrity of myelinated white matter in patients with multiple sclerosis. Lesional MTR decreases in the acute phase due to demyelination, and subsequently shows recovery depending on the degree of remyelination in the absence of axonal loss. Recovery of average lesion MTR therefore might prove a viable outcome measure to assess the effect of remyelinating agents. Our objective was to determine the required sample size for phase II multicentre clinical trials using the recovery of average lesion MTR as primary outcome measure. With 7-monthly MRI scans, the MTR evolution of 349 new enhancing lesions before and after enhancement was assessed in 32 MS patients from 5 centres. Multilevel models were fitted to the data yielding estimates for the variance components, which were applied in power calculations. Sample sizes were determined for placebo-controlled, multicentre trials using lesional MTR recovery post-enhancement as primary outcome measure. Average lesion MTR decreased slightly in the build-up to enhancement, decreased dramatically during enhancement and showed recovery in the period after cessation. The power calculations showed that for a power of 80%, approximately 136 patients per trial (mean number of 6 lesions per patient) are required to detect a 30% increase in lesional MTR post-enhancement compared with placebo, whereas 48 subjects are required to detect a 50% increase in lesional MTR compared with placebo. Recovery of lesion MTR is a feasible outcome measure for future multicentre clinical trials measuring the effect of remyelinating agents.Keywords
This publication has 19 references indexed in Scilit:
- A sensitive, noise-resistant method for identifying focal demyelination and remyelination in patients with multiple sclerosis via voxel-wise changes in magnetization transfer ratioJournal of the Neurological Sciences, 2009
- Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosisMultiple Sclerosis Journal, 2008
- Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesionsAnnals of Neurology, 2008
- Sources of variation in multi-centre brain MTR histogram studies: body-coil transmission eliminates inter-centre differencesMagnetic Resonance Materials in Physics, Biology and Medicine, 2006
- Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosisBrain, 2006
- Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patientsNeurology, 2005
- Magnetization transfer ratio and myelin in postmortem multiple sclerosis brainAnnals of Neurology, 2004
- Magnetization transfer ratio in new MS lesions before and during therapy with IFNβ-1aNeurology, 2000
- Magnetization transfer changes in the normal appering white matter precede the appearance of enhancing lesions in patients with multiple sclerosisAnnals of Neurology, 1998
- Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathologyAnnals of Neurology, 1997